Viatris Inc (VTRS): Completion of Acquisition or Disposition of Assets

Viatris Inc (VTRS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Viatris Completes Acquisition of Pacira BioSciences PITTSBURGH – Nov. 17, 2026 – Viatris Inc. (“Viatris”) (Nasdaq: VTRS), a global healthcare company, today announced that it has completed its acquisition of Pacira BioSciences, Inc. (“Pacira”) (Nasdaq: PCRX), a leade

Event · M&A · completed
Role
acquirer
Counterparty
Pacira BioSciences, Inc.
Price per share
$36.50 per Share
Consideration
cash

Facts are quoted from the filing text and checked against it. Details that could not be matched to the text are left out.

Original reporting
Published Nov 17, 2026, 2:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 2:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMergers & acquisitions
Primary signal
$VTRS
Bullish
medium confidence
Mentioned
$VTRS
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$VTRSBullishMed
01

Why it matters

The transaction is now consummated: tender offer expired Nov. 16, Viatris accepted validly tendered shares, Purchaser merged into Pacira, and Pacira will be delisted. Viatris expects the acquisition to contribute $90 million to $100 million of total revenues for the remainder of 2026.

02

Market read

Traders can update positioning now that the acquisition is closed and a near-term revenue contribution range is provided.

03

What to watch

Post-close performance will depend on commercialization of Pacira’s portfolio and whether cost synergies and earnings growth materialize as guided.

Relevance 8/10Novelty 7/10Timing: deal close reported in an SEC 8-K on Nov. 17, 2026

Background

Viatris announced the Pacira tender offer on Oct. 8, 2026 and this 8-K reports completion of the acquisition/disposition of assets.

Company-level read

Ticker impact

$VTRSBullishMedium confidence
Context

Viatris completed its Pacira acquisition, accepted tendered shares, and will delist Pacira after the merger closes.

Expected impact

Likely modest upside bias as the market prices the completed acquisition and the stated 2026 revenue contribution.

Evidence & confidence

The filing confirms tender acceptance, merger completion, and provides a specific incremental revenue range for the remainder of 2026, which can affect near-term expectations.

Market effects

Reinforces consolidation in specialty pharma/pain management and may shift read-through expectations for non-opioid pain competitors.

Primarily US-listed healthcare M&A sentiment; limited direct regional spillover beyond US healthcare investors.

Global healthcare investors may re-rate US pain-management assets as deal execution risk declines.

Counterpoint

The revenue contribution range is only for the remainder of 2026, so the market may focus on longer-term integration and synergy realization rather than the close itself.

Key entities

  • Viatris Inc

    Nasdaq-listed acquirer completing the Pacira tender offer and merger.

  • Pacira BioSciences, Inc.

    Nasdaq-listed target being acquired and delisted after the merger closes.

  • Peach Purchaser Sub Inc.

    Wholly owned Viatris subsidiary that accepted tendered shares and merged into Pacira.

Related articles

$VTRSMedAI 8/10

Viatris Completes Acquisition of Pacira BioSciences

Viatris Inc. (VTRS) completed its acquisition of Pacira BioSciences (PCRX) for $36.50 per share. The deal, announced in October, aims to strengthen Viatris's U.S. pain management business. Pacira's shares will be delisted from Nasdaq, and Viatris expects the acquisition to add $90M-$100M in revenue for the rest of 2026.